Belghith Mériam, Bluestone Jeffrey A, Barriot Samia, Mégret Jérôme, Bach Jean-François, Chatenoud Lucienne
INSERM U580, IRNEM, Hôpital Necker, 161 Rue de Sèvres, 75015 Paris, France.
Nat Med. 2003 Sep;9(9):1202-8. doi: 10.1038/nm924. Epub 2003 Aug 24.
CD3-specific antibodies have the unique capacity to restore self-tolerance in established autoimmunity. They induce long-term remission of overt diabetes in nonobese diabetic (NOD) mice and in human type I diabetes. The underlying mechanisms had been unclear until now. Here we report that treatment with CD3epsilon-specific antibodies induces transferable T-cell-mediated tolerance involving CD4+CD25+ cells. However, these CD4+CD25+ T cells are distinct from naturally occurring regulatory T cells that control physiological autoreactivity. CD3-specific antibody treatment induced remission in NOD Cd28-/- mice that were devoid of such regulatory cells. Remission of diabetes was abrogated by coadministration of a neutralizing transforming growth factor (TGF)-beta-specific antibody. The central role of TGF-beta was further suggested by its increased, long-lasting production by CD4+ T cells from tolerant mice. These data explain the intriguing tolerogenic effect of CD3-specific antibodies and position them as the first clinically applicable pharmacological stimulant of TGF-beta-producing regulatory CD4+ T cells.
抗CD3特异性抗体具有恢复已建立的自身免疫中自身耐受性的独特能力。它们能诱导非肥胖糖尿病(NOD)小鼠和人类I型糖尿病患者的显性糖尿病长期缓解。直到现在,其潜在机制仍不清楚。在此我们报告,用抗CD3ε特异性抗体治疗可诱导涉及CD4+CD25+细胞的可转移的T细胞介导的耐受性。然而,这些CD4+CD25+ T细胞不同于控制生理性自身反应性的天然存在的调节性T细胞。抗CD3特异性抗体治疗可使缺乏此类调节细胞的NOD Cd28-/-小鼠的糖尿病缓解。通过共同给予中和性转化生长因子(TGF)-β特异性抗体,可消除糖尿病缓解。来自耐受小鼠的CD4+ T细胞产生的TGF-β增加且持久,这进一步表明了TGF-β的核心作用。这些数据解释了抗CD3特异性抗体引人关注的致耐受性作用,并将它们定位为产生TGF-β的调节性CD4+ T细胞的首个临床适用的药理学刺激剂。